Journal
VACCINE
Volume 31, Issue -, Pages K98-K112Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2013.04.088
Keywords
Mini-Sentinel; PRISM; Vaccine; Health outcome; Data characterization; Surveillance
Categories
Funding
- Food and Drug Administration (FDA) through Department of Health and Human Services (HHS) [HHSF223200910006I]
- Mini-Sentinel program
Ask authors/readers for more resources
Background: The Post-Licensure Rapid Immunization Safety Monitoring (PRISM) program is the immunization safety monitoring component of FDA's Mini-Sentinel project, a program to actively monitor the safety of medical products using electronic health information. FDA sought to assess the surveillance capabilities of this large claims-based distributed database for vaccine safety surveillance by characterizing the underlying data. Methods: We characterized data available on vaccine exposures in PRISM, estimated how much additional data was gained by matching with select state and local immunization registries, and compared vaccination coverage estimates based on PRISM data with other available data sources. We generated rates of computerized codes representing potential health outcomes relevant to vaccine safety monitoring. Standardized algorithms including ICD-9 codes, number of codes required, exclusion criteria and location of the encounter were used to obtain the background rates. Results: The majority of the vaccines routinely administered to infants, children, adolescents and adults were well captured by claims data Immunization registry data in up to seven states comprised between 5% and 9% of data for all vaccine categories with the exception of 10% for hepatitis B and 3% and 4% for rotavirus and zoster respectively. Vaccination coverage estimates based on PRISM's computerized data were similar to but lower than coverage estimates from the National Immunization Survey and Healthcare Effectiveness Data and Information Set. For the 25 health outcomes of interest studied, the rates of potential outcomes based on ICD-9 codes were generally higher than rates described in the literature, which are typically clinically confirmed cases. Conclusion: PRISM program's data on vaccine exposures and health outcomes appear complete enough to support robust safety monitoring. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available